CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Pres... (continued businessdevelopment efforts he...)

CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases

Date:2/11/2008

continued business development efforts headed by Tony Colasin, who was previously Senior Director of Business Development at ICOS, which was recently acquired by Lilly.

About CellCyte Genetics

CellCyte Genetics, a Washington State company, is an emerging biotechnology company engaged in the principal business of the discovery, development and commercialization of breakthrough stem cell enabling therapeutic products for use in regenerative medicine. The Company also has a medical device division being developed to grow and expand a variety of cells including Islet cells for diabetes and eventually proteins.

For further information see: http://www.cellcyte.com.

Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.

Safe Harbor Statement

THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD- LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH THE CLOSING OF THE SHARE EXCHA
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
2. Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation
3. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
4. Hagens Berman Sobol Shapiro Announces Proposed Class-Action Lawsuit Against CellCyte
5. Hagens Berman Sobol Shapiro Investigating CellCyte
6. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
7. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
8. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
9. Smart Genetics Announces Plans to Launch a New Alzheimers Risk Assessment Service
10. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
11. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock

Post Your Comments:

CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Pres...(continued businessdevelopment efforts he...)